The European College of Neuropsychopharmacology (ECNP) Medicines Chest Initiative: Rationale and Promise
- 54 Downloads
Development of drugs for treating diseases of the central nervous system (CNS) has had some of the highest attrition rates in the pharmaceutical industry, and the high risk and cost of development has led to many companies withdrawing from the area, despite significant unmet medical needs remaining and, hence, large commercial potential. For many CNS diseases, particularly psychiatric diseases, our understanding of the fundamental neuroscience associated with the disease is limited, which has led to a lack of predictivity of animal models and, therefore, often a failure of translation from animal models into human patients. Fortunately, technologies such as genetics and functional imaging are rapidly advancing our understanding of the human brain. Historically, many drugs used to treat CNS disorders were discovered by serendipity, when activity was noticed in the clinic during use for another indication. Such clinical ‘repurposing’ of drugs is still a highly useful strategy, but requires the availability of selective and potent tool compounds, with an accompanying regulatory data package, that will allow their use in people. Many such compounds exist within pharmaceutical companies but are sitting on the shelf because their development has been terminated. The Medicines Chest initiative was set up, funded by the European College of Neuropsychopharmacology (ECNP), in order to gain access to such compounds, so they could be used by academics and small companies in experimental medicine studies. The purpose of this article is to provide an update on progress with this initiative.
KeywordsNeuropathic Pain Pregabalin Zolpidem Central Nervous System Disease Tiagabine
We would like to acknowledge the contribution of Dr. Gavin Kilpatrick in helping to set up the Medicines Chest.
Compliance with Ethical Standards
No funding was received for the publication of this article.
Conflict of interest
David Nutt has no conflicts of interest to report. Ann Hayes has received consulting fees and expenses from the European College of Neuropsychopharmacology (ECNP) for setting up the Medicines Chest.
- 1.Angelman Syndrome Foundation. Upcoming Angelman syndrome clinical trial. http://www.angelman.org/news/upcoming-angelman-syndrome-clinical-trial/. Accessed 13 Aug 2015.
- 8.ECNP. ECNP Medicines Chest. http://www.ecnp.eu/projects-initiatives/ECNP-medicines-chest.aspx. Accessed 13 Aug 2015.
- 17.Nutt D, Wilson S, Lingford-Hughes A, Myers J, Papadopoulos A, Muthukumaraswamy S. Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: a study in healthy volunteers. Neuropharmacology. 2015;88:155–63.CrossRefPubMedGoogle Scholar
- 19.Raasch W. Central nervous system drug market. In: Wikinvest. http://www.wikinvest.com/wiki/Central_Nervous_System_Drug_Market. Accessed 13 Aug 2015.